The Health Implementation Communiqué (SUT) is no longer an annually updated text but a continuously rewritten living document. Within 2026 alone, five separate amendment decrees were published from January to July — and six including December 2025: 31.12.2025, 17.01.2026, 08.04.2026, 23.05.2026, 29.06.2026 and 01.07.2026. This tempo changes the operating model of every reimbursement team: instead of a periodic "SUT revision analysis", what is required is continuous monitoring and product-level impact assessment. This article examines the content of the wave, why certain annexes and articles are critical, and the operational response companies should mount.
What the SUT is, its legal basis and structure
The SUT is a communiqué issued by the Social Security Institution (SGK) under the authority of Law No. 5510 on Social Insurance and General Health Insurance, governing the health services, medicines, medical devices and payment conditions the Institution will cover. First published in 2013, it has since been updated by more than a hundred amendment decrees, and the current text is tracked in consolidated form.
Its structure is annex-centred, and which annex changed determines the direction of analysis: Annex-1 the drug list (products not on the market / requiring import), Annex-2/A products not covered, Annex-2/B disease-based coverage, Annex-2/C the off-label use list, Annexes 4/A-4/B-4/C-4/D reimbursement lists in different statuses, Annex-2 procedure point lists, Annex-3 medical device annexes, and the main text governing per-service payment rules. Seeing "Annex-4/C amendment" in a decree points you to the drug side; "procedure points" to services; "devices" to device annexes.
The amendment mechanism and calendar discipline
SUT amendments enter into force through amendment decrees published in the Official Gazette, resulting from preparatory work by the SGK's Health Services Pricing Supreme Council and relevant commissions. Decrees generally take effect the day after publication or after a short transition period; retroactive corrections and repeal provisions can sit in the same text. Monitoring must therefore operate in three timeframes: pre-publication (draft and agenda tracking), publication day (official text scanning) and post-effect (billing verification).
The Annex-4/C wave: euro-based prices, barcode changes, delistings
The most intense updating in the latest wave hit Annex-4/C. This annex covers medicines not marketed in Türkiye or impossible to find on the market, supplied from abroad under special import status, typically priced in euro. Amendment decrees show three types of movement here: price revisions, barcode/name corrections, and list changes (removals/additions).
In the latest wave, euro-based prices of numerous products were revised on cost-increase grounds; some barcodes and names were changed; some products were removed and new ones added. Rare-disease medicines saw striking examples: one growth-hormone product's listed price moved from EUR 62 to EUR 680; different forms of another product were updated to EUR 890 and EUR 2,490. Active substances including mecasermin, amifampridine, pegaspargase, flecainide acetate, tetrabenazine, dapsone, colchicine and rufinamide had their price, name and record details changed.
The operational meaning is clear: for Annex-4/C products, price and barcode matches must be re-verified after every decree. A broken barcode produces query inconsistencies in pharmacy and hospital information systems; invoice-list mismatches end in payment rejections. For every actor in the importer-distributor chain, the first task after a decree is list verification.
The SMA example: how to read indication-level criteria revisions
Article 4.2.49 of the SUT on Spinal Muscular Atrophy (SMA) — the principles for nusinersen sodium and risdiplam — was revised. Such revisions change three things at once: patient selection criteria (who qualifies), application and approval processes (which documents, which commission) and billing rules (which doses, at what intervals). A narrowing shrinks the patient pool, a widening grows it; in both directions the budget-impact forecast and supply plan must be rebuilt.
Indication-level changes recur periodically in oncology and rare diseases. Every change demands a re-reading of the product's reimbursement strategy: were the patient-number assumptions in the file built on current criteria, are advisory-board recommendations aligned, is physician education material up to date? It is not enough for medical affairs to read the change; market access must run a file-level impact analysis.
The services side: new procedures enter coverage
Beyond medicines, new medical procedures entered public coverage: bronchoscopic cryobiopsy, EBUS-guided transbronchial cryobiopsy and bronchial thermoplasty for asthma patients, plus polysomnography and the multiple sleep latency test for sleep disorders. This expansion in respiratory care improved access for the relevant patient groups and changed volume planning for the centres performing them.
Procedure points and device payment values were also updated: reimbursement values for devices used in cardiology and spinal surgery were revised. For device companies, a point update directly changes the product's position in hospital economics; sales arguments must be rebuilt on current point values. The wave also brought new arrangements in home care and home physiotherapy, where per-patient payment rules and session limits must be tracked together.
Off-label use: Annex-2/C dynamics
Off-label use is one of the most-used mechanisms in oncology practice. List entries and exits come to the agenda when a new licence/reimbursement decision arrives for the indication or when the scientific justification weakens. The latest wave also saw list movements; continuity of access for patients within off-label oncology coverage requires reading the changes together with transitional provisions: will patients under treatment continue, will new patient intake stop? The answers lie in the decree's temporary articles.
The SUT monitoring operation: a three-layer model
- Scanning layer: tracking the Official Gazette, SGK announcements and consolidated-SUT text services; summarising every decree article by article.
- Analysis layer: converting change notes into product/service-level impact analyses — which barcodes were affected, which indication criteria changed, which procedure points were revised.
- Action layer: billing and system updates (pharmacy/hospital information systems, internal price lists), updates to medical education materials and, where necessary, requests for meetings with the Institution.
The heart of the model is the analysis layer. An impact-analysis template should have four columns: the changed provision (article/annex reference), the affected product/service (barcode/procedure code), the impact type (price, criteria, scope, process) and the responsible team + deadline. When every decree is entered into this template, inter-team coordination moves from email traffic into institutional memory.
Reflections on the reimbursement file
SUT amendments directly affect three assumptions in file preparation. First, the price assumption: costing is done with SUT prices, and price revisions change model outputs. Second, the patient-number assumption: when indication criteria are revised, prevalence-incidence projections must be rebuilt on current criteria. Third, comparator selection: newly covered therapies or those falling out of coverage change the comparator set and market-share scenarios. For every product with a file in preparation, the question "how have the latest SUT amendments been reflected in the file" must be a mandatory pre-delivery check.
The company's 2026 calendar: an action plan
- Permanent monitoring: set Official Gazette and SGK announcement tracking to a weekly rhythm; name responsible staff and backups.
- Product map: build a one-page map showing each product in your portfolio's place in the SUT (which annex, which article, which criteria).
- Decree protocols: write down the first-48-hour actions when a new decree arrives (list verification, system updates, team briefing).
- Impact-analysis archive: keep the analyses produced for each decree as institutional memory; use them in advisory boards and Institution meetings.
- File synchronisation: make an SUT-revision check a delivery precondition on active file projects.
Case study: the first 48 hours after a decree for an Annex-4/C product
A fictional but realistic scenario. A rare-disease medicine is supplied under Annex-4/C at a euro-based price; the 01.07.2026 decree changes its barcode and revises the price. First hours (0-4): the decree text is located; the product's barcode and price lines are extracted into a comparison table; impact confirmed. Morning (4-8): regulatory affairs distributes the change summary; supply/import runs the stop-verify-reopen chain on the new barcode. Day one (8-24): the pharmacist and hospital notification note is prepared (operational, not promotional); customer-service scripts are updated; the flow for patients under treatment is dry-run to avoid interruption. Day two (24-48): billing systems are tested; correction applications are planned for lines carrying rejection risk; the impact-analysis template is completed and filed into institutional memory. The presence or absence of this 48-hour protocol is the difference between patients interrupting therapy or not.
A glossary of SUT annexes: what each annex tells you
New teams struggle most with mixing annex functions. A short glossary: Annex-1 — drugs covered by the Institution but not on the Turkish market; supply tied to import authorisation. Annex-2/A — drugs not covered (exclusion list). Annex-2/B — drugs covered without diagnosis-based restriction. Annex-2/C — drugs covered for off-label use; each line carries indication and condition definitions. Annex-4/A — priced drugs within reimbursement. Annex-4/B — unpriced/special-status products. Annex-4/C — products supplied from abroad (special import). Annex-4/D — products under disease-based special conditions. Annex-2B/2C procedure point lists — per-service and diagnosis-based procedure points. This glossary is the reading key to decree scanning; keep your product map in this annex terminology, and the question "where does my product fall" in every new decree is answered in seconds.
Budget impact and forecast revision: how a decree flows into planning
SUT amendments reach commercial planning through three channels. Price channel: in products entering/leaving coverage, list and net prices change; the sales forecast is rebuilt on the new price. Volume channel: indication-criteria revisions change patient numbers; forecasts are revised down on narrowing and up on widening, and supply plans tied to them. Process channel: changes in application conditions (new board approval, extra documentation) can lengthen the sales cycle; delivery estimates should carry delay buffers. Good financial practice is presenting management a one-page report after every decree: affected products + budget-impact estimate + action.
Objection and correction routes with the Institution
When an interpretation adverse to your product appears in decree implementation (a wrong barcode match, a criteria reading), passivity is the worst option. The route has three steps: (1) Written documentation: the provision's source in the decree text, implementation examples and product-level impact. (2) Information and opinion requests: asking the rationale through institutional channels; where appropriate, carrying a joint message through sector associations. (3) Correction proposal: where a technical fix is required (barcode, name, amount), following the Institution's own correction practice and filing for the record update. All routes run faster for firms with an impact-analysis archive; undocumented objection finds no echo at the Institution.
A glossary: the language of the reimbursement file
Learning the file's language through shared definitions accelerates cross-team communication. Reimbursement commission: the institutional structure evaluating coverage of medicines; files are tabled to it. Technical committee/sub-committee: the layer of clinical and pharmacotherapeutic assessment with expert physician participation. Submission: the entirety of the company's application — forms, clinical and economic sections, pricing information and annexes. Indication restriction: the SUT definition of the patient group to be covered, expressed as "provided the criteria sought for the condition are met". Conditional coverage: reimbursement conditional on prerequisites such as board reports or commission approval. List price/net price: the official amount set through pricing versus the realised amount after rebates; both are managed separately in files and negotiations. Barcode matching: the product's identity match in payer systems; a break produces payment rejections. Publication/effect dates: the day the amendment appears in the Official Gazette versus the day it applies — the interim is the transition period. Realisation report: the payer's monitoring of amounts paid; the ex-post control of budget impact. Turning this glossary into internal training material measurably accelerates file preparation.
Through the decision-maker's eyes: what does the payer ask?
Knowing the assessor's question set is preparation's most valuable part. Typical payer questions: "What annual load does this product bring to my budget?" — the reliability of budget-impact forecasts is tested against the realism of market-share assumptions. "Is the comparator right?" — was the genuinely preferred local treatment referenced? "Where do patient numbers come from?" — the method of adapting prevalence to Türkiye is questioned. "How is the usage criterion audited?" — the enforceability of the indication restriction is tested against board processes. "Is there a domestic-manufacturing dimension?" — industrial policy is on the evaluation agenda. "Is there an equivalent, and what is the difference?" — whether the added-benefit narrative is supported with local data. A file prepared for these questions in advance moves through the commission's agenda in fewer rounds; an unprepared one stretches for months on completion requests. In our experience, the biggest accelerator of file timelines is not the polish of the first submission but the first submission being constructed around this question set.
A product-level SUT monitoring template: the worksheet
The recommended per-product monitoring sheet carries these blocks. Identity: product name, active substance, barcode(s), company, licence date, pricing status. Coverage: which annex the product sits in (Annex-1, 2/C, 4/A...), which SUT article covers it, the indication-restriction text, conditional-payment requirements (board approval etc.). History: coverage-entry date, the list of criteria/price changes experienced (with decree references). Risk: expected changes ahead — likelihood of criteria revision, comparator movements, Annex-4/C price risk, barcode-change risk. Action: for each risk, the responsible person and the document set to be kept ready. Making this one-page sheet the shared document across departments cuts the time lost at decree moment from hours to minutes; it is also a quality exhibit showing the firm's seriousness in advisory boards and payer meetings.
Where SUT meets promotion law: coverage is not a promotion permit
A common conceptual error is treating an indication that entered reimbursement as automatically permitted for promotion. The two regimes answer different questions: the SUT asks "for whom will it be paid?", promotion law asks "what may be said to whom?". Your product may be covered for an off-label use under Annex-2/C; that solves the billing side but not the promotion side — promotion is allowed only within the approved indication, and materials are bounded by the approved SmPC. The intersection is critical in oncology teams: even medical responses to physician questions must pass through a process that binds the information-versus-promotion distinction. A compliance programme teaching this distinction explicitly prevents the field team from crossing the line in good faith.
Sources and key takeaways
Core sources: the SUT (consolidated text) and the amendment decrees of 31.12.2025-01.07.2026; SGK announcements and annex files; sector assessments of each decree. Recommended monitoring: the SGK legislation pages weekly, the Official Gazette daily; commercial comparison-table services should serve as the single internal source. Our key takeaways: (1) SUT monitoring is now a permanent capability — build the three-layer model (scan/analyse/act); (2) re-verify Annex-4/C barcode-price matches after every decree; (3) criteria revisions resize the patient pool and file assumptions — re-run models; (4) the impact-analysis template is the backbone of institutional memory and payer meetings; (5) make the "latest SUT changes reflected?" check a mandatory pre-delivery item.
Conclusion
The 2026 wave has shown that SUT tracking is no longer a year-end closing exercise but a permanent corporate capability. The teams that win are those that translate decrees into product impact and action. To analyse how SUT amendments affect your product, reposition your reimbursement file with current criteria and institutionalise your monitoring processes, leverage Omega Arastirma's legislative monitoring and impact-analysis support. Reach us via the service application form.